Cassava Sciences Inc vs Rent the Runway Inc — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Rent the Runway Inc trades at $1.73 (market cap $61.75M). The key difference: Rent the Runway Inc is the larger of the two by market cap, and Cassava Sciences Inc is more actively traded (759,018 versus 193,323). Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Rent the Runway Inc for 56 Days on average.
| FLNA | RENT | |
|---|---|---|
Market Cap | $39.40M | $61.75M |
Volume | 759,018 | 193,323 |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $9.39 |
52-Week Low | $0.68 | $1.55 |
Typical Hold Time | 37 Days | 56 Days |
Enterprise Value | -$43.28M | $228.75M |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.
The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.
RENT trades at $1.765, up 5.06% today, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported revenue of $306.20M in 2025 with improving net loss margins, yet negative shareholder equity and high debt-to-asset ratios persist. Recent news includes a CEO appointment and multiple law firm investigations into investor claims, creating a complex sentiment backdrop.
The outlook remains challenged by financial instability and legal scrutiny, though analyst consensus leans buy with no sell ratings. Key risks include high leverage and ongoing losses, while potential upside hinges on execution of growth initiatives and margin improvement. Investors face significant volatility amid restructuring efforts.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe, or buy designer apparel and accessories.
Read more on RENT →